Related Experiment Videos
Summary
Cancer risk increases in kidney transplant recipients due to transplanted or de novo malignancies. Common cancers include skin, lip, and lymphomas, with lymphomas often affecting the central nervous system. Immunosuppression management is key.
Area of Science:
- Nephrology
- Oncology
- Immunology
Background:
- Renal homograft recipients exhibit a higher incidence of cancer.
- Malignancies can be transplanted with the donor kidney or develop de novo post-transplant.
- De novo tumors typically appear around 34 months after transplantation.
Purpose of the Study:
- To review the types and incidence of malignancies in renal transplant recipients.
- To discuss management strategies for cancer in this patient population.
- To assess the impact of malignancy on renal transplantation outcomes.
Main Methods:
- Review of existing literature on cancer incidence in renal transplant recipients.
- Analysis of common tumor types and their characteristics.
- Discussion of treatment implications, including immunosuppression adjustment.
Main Results:
- Common malignancies include skin and lip carcinomas, lymphomas (primarily reticulum cell sarcomas), and cervical carcinomas.
- Lymphomas show a predilection for the central nervous system.
- The overall mortality rate from cancer in kidney homograft recipients is low.
Conclusions:
- Malignancy development does not contraindicate renal transplantation.
- Reduction or cessation of immunosuppression may be considered alongside conventional cancer therapy.
- Careful monitoring and management are essential for renal transplant recipients at risk for cancer.